3055 POSTER Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study

C.de Cerqueira Mathias; F.Perazzo; S.Simon; L.Fein; J.Hidalgo; A.M.Murad; G.Lerzo; R.Esser; S.Scheid; A.C.Buzaid

首页> 外文期刊>European Journal of Cancer Supplements >3055 POSTER Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study

【24h】

3055 POSTER Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study

机译：3055 POSTER西妥昔单抗联合伊立替康在先前的伊立替康治疗期间或之后进展为转移性结直肠癌（mCRC）的患者（pts）：LABEL研究的最终结果

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements 》 |2007年第4期| 共2页
作者
C.de Cerqueira Mathias; F.Perazzo; S.Simon; L.Fein; J.Hidalgo; A.M.Murad; G.Lerzo; R.Esser; S.Scheid; A.C.Buzaid;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. 3025 POSTER Impact of pre-medication on the frequency of infusion-related reactions (IRRs) and efficacy in patients (pts) treated with cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): the MABEL study [J] . H.Wilke, S.Siena, J.Thaler, European Journal of Cancer Supplements . 2007 ,第4期

机译：3025 POSTER服药前对西妥昔单抗联合伊立替康治疗转移性结直肠癌（mCRC）的患者输注相关反应（IRR）的频率和疗效的影响：MABEL研究
2. 3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial [J] . W.Scheithauer, A.Sobrero, H.J.Lenz, European Journal of Cancer Supplements . 2007 ,第4期

机译：EPIC试验：3003口服西妥昔单抗联合伊立替康治疗转移性结直肠癌（mCRC）失败的患者（以奥沙利铂为基础的治疗）
3. 3068 POSTER Capecitabine + irinotecan + bevacizumab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results [J] . S.Beslija, M.Banjin, S.Jungic, European Journal of Cancer Supplements . 2007 ,第4期

机译：3068 POSTER卡培他滨+伊立替康+贝伐单抗作为转移性结直肠癌（MCRC）患者（pts）的一线治疗：II期初步研究结果
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Use and outcomes of newer chemotherapeutic agents in colorectal cancer patients using Irinotecan as a case study. [D] . Obeidat, Nour A. 2008

机译：以伊立替康为例的结直肠癌患者中新型化疗药物的使用和结果。
6. Safety and Effectiveness of Aflibercept + Fluorouracil Leucovorin and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study [O] . Ian Chau, Marwan Fakih, Pilar García-Alfonso, 2020

机译：OZONE研究显示Aflibercept +氟尿嘧啶白叶三醇和伊立替康（FOLFIRI）治疗转移性结直肠癌（mCRC）患者的安全性和有效性
7. CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress [O] . M. Shah, A. Grothey, N. Tebbutt, 2018

机译：Canstem303C试验：在成年患者（PTS）中与先前治疗的转移性结肠直肠癌（MCRC）的成人患者（PTS）组合的纳帕布桑（NAPA）与5-氟尿嘧啶（5-FU），Leucovorin和Irinotecan（Folfiri）的相结合研究 - 试验

3055 POSTER Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study

著录项

相似文献

相关主题

期刊订阅